Parabilis Medicines, Inc.
PBLSUnited States
1 filed reports · 116 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
1 reports · Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 1 | 179 | Jun 2026 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 13, 2026 | 179 | Open |
Financial data
116 concepts · 179 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial114 concepts · 165 facts · Nov 2024 to Jun 2026
- Stockholders equity (US GAAP)6 · Dec 2024 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents4 · Dec 2024 to Jun 2026
- Fair value measurement with unobservable inputs reconciliations recurring basis liability value4 · Dec 2024 to Jun 2026
- Net income loss4 · Mar 2025 to Jun 2026
- Stock issued during period value share based compensation4 · Mar 2025 to Jun 2026
- AOCI Attributable to Parent3 · Mar 2025 to Jun 2026
- Stock issued during period value stock options exercised3 · Jun 2025 to Jun 2026
- Allocated share based compensation expense2 · Jun 2025 to Jun 2026
- Antidilutive securities excluded from computation of earnings per share amount2 · Jun 2025 to Jun 2026
- Cash and cash equivalents at carrying value2 · Jun 2025 to Jun 2026
- Change in fair value of simple agreement for future equity2 · Jun 2025 to Jun 2026
- Comprehensive income net of tax including portion attributable to noncontrolling interest2 · Jun 2025 to Jun 2026
- Cumulative dividends on convertible preferred stock2 · Jun 2025 to Jun 2026
- Defined contribution plan cost recognized2 · Jun 2025 to Jun 2026
- Depreciation and amortization2 · Jun 2025 to Jun 2026
- Earnings per share basic2 · Jun 2025 to Jun 2026
- Earnings per share diluted2 · Jun 2025 to Jun 2026
- General and administrative expense (US GAAP)2 · Jun 2025 to Jun 2026
- Incremental common shares attributable to contingently issuable shares2 · Jun 2025 to Jun 2026
- Interest expense nonoperating2 · Jun 2025 to Jun 2026
- Interest income other2 · Jun 2025 to Jun 2026
- Net income loss available to common stockholders basic2 · Jun 2025 to Jun 2026
- Nonoperating income expense2 · Jun 2025 to Jun 2026
- Operating expenses (US GAAP)2 · Jun 2025 to Jun 2026
Product2 concepts · 14 facts · Jun 2025 to Jun 2026
- Operating costs and expenses10 · Jun 2025 to Jun 2026
- Other research and development expense4 · Jun 2025 to Jun 2026
Segments
14 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or service7 members · 14 facts
- External Research And Development Expense ARON2 · Jun 2025 to Jun 2026
- External Research And Development Expense Catenin Degrader2 · Jun 2025 to Jun 2026
- External Research And Development Expense Early Discovery And Other Programs2 · Jun 2025 to Jun 2026
- External Research And Development Expense ERG2 · Jun 2025 to Jun 2026
- External Research And Development Expense Zolucatetide2 · Jun 2025 to Jun 2026
- Personnel- Related General And Administrative Expenses2 · Jun 2025 to Jun 2026
- Personnel Related Research And Development Expenses2 · Jun 2025 to Jun 2026
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.